Coating Module Supports Easy Module Exchange

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-07-02-2017
Volume 41
Issue 7
Pages: 12

Tablet coating from DISONA can handle batch sizes up to 3 kg.

The new tablet coating module for the Minilab XP from DIOSNA supports easy module exchange, without the need for disassembling. The module is available for batch sizes from 500 g up to 3 kg. The module is equipped with a glass lid for process observation. Both modules are operated by a full graphical display, which allows for a change between manual and automatic modes. 

DIOSNA

 

 

Download Issue PDF
Articles in this issue
Packaging Improves Medication Adherence
Packaging Improves Medication Adherence
The New World of Biopharmaceutical Manufacturing
The New World of Biopharmaceutical Manufacturing
Forty Years of Drug Product Manufacturing Advances
Forty Years of Drug Product Manufacturing Advances
PT0717_Cover_200.jpg
Evolution of Dosage-Form Development and Manufacturing Strategies
Advances in Analytical Testing Tools for the Bio/Pharma Industry
Advances in Analytical Testing Tools for the Bio/Pharma Industry
PT0717_spotlignt_Ross_42N-36S.jpg
Ribbon Blenders for Specialty Applications
PT0717_spotlight_doisna_MiniCoater.jpg
Coating Module Supports Easy Module Exchange
PT0717_ProdSpotlight_distek.jpg
Dissolution Tester Eliminates Water Bath
PT0717_spotlight_sartorius_biostat_str_500.jpg
Bioreactor Family Includes Single-Use Bags
FDA Continues to Promote Quality Drug Production
FDA Continues to Promote Quality Drug Production
A 30-Year History of PLG Applications in Parenteral Controlled Drug Release
A 30-Year History of PLG Applications in Parenteral Controlled Drug Release
Coatings Sweeten Pharma Tablet Production
Coatings Sweeten Pharma Tablet Production
PT0717_Cover_200-6.jpg
Continuous API Manufacturing
PT0717_OSD_fig3Innopharma_250.jpg
Moving Toward Real-Time Release Testing
PT0717_Cover_200-8.jpg
Advances in ADCs
Recent Videos
Jens Schmidt, associate director MSAT at Lonza
Behind the Headlines episode 8
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Roger Viney, PhD, chief commercial officer for ICE Pharma
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Gerresheimer and Bormioli Pharma to Showcase Containment Solutions at Pharmapack

Susan Haigney
January 20th 2025
Article

The two companies will be exhibiting together after Gerresheimer’s December 2024 acquisition of Bormioli.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

Lonza and Iconovo Team Up on Intranasal Biologic Candidate

Feliza Mirasol
January 15th 2025
Article

Lonza will work with Iconovo to develop spray-dried formulations for an intranasally delivered biologic using a reformulated biologic drug candidate for obesity.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

With New Funding, Orbis Medicines to Develop Oral Macrocycles as Alternative to Biologic Drugs

Feliza Mirasol
January 7th 2025
Article

With the new $94 million (€90 million) funding, the company will develop its pipeline of oral macrocycle drugs, nCycles, against validated biologic targets.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Takeda Receives Japanese Regulatory Approval for HYQVIA Subcutaneous Injection for Treating Agammaglobulinemia or Hypogammaglobulinemia

Feliza Mirasol
January 4th 2025
Article

With this approval, HYQVIA [Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase] becomes the first and only facilitated subcutaneous immunoglobulin available in Japan to treat these disorders.